Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.

MLA

Jung, Hye-Sol, et al. “Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.” Cancers, vol. 14, no. 18, Sept. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.3390/cancers14184360.

APA

Jung, H.-S., Kim, H. S., Kang, J. S., Kang, Y. H., Sohn, H. J., Byun, Y., Han, Y., Yun, W.-G., Cho, Y. J., Lee, M., Kwon, W., & Jang, J.-Y. (2022). Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 14(18), N.PAG. https://doi.org/10.3390/cancers14184360

Chicago

Jung, Hye-Sol, Hyeong Seok Kim, Jae Seung Kang, Yoon Hyung Kang, Hee Ju Sohn, Yoonhyeong Byun, Youngmin Han, et al. 2022. “Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.” Cancers 14 (18): N.PAG. doi:10.3390/cancers14184360.